8-K 1 a8-kdyadicvttachivingg.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 19, 2020

Dyadic International, Inc.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) | 000-55264 (Commission File Number) | 45-0486747 (I.R.S. Employer Identification Number)
140 Intracoastal Pointe Drive, Suite 404 Jupiter, FL 33477 |  |
(Address of principal executive offices and zip code) |  |
(561) 743-8333 |  |
(Registrant’s telephone number, including area code) |  |
N/A (Former Name or Former Address, if Changed Since Last Report) |  |

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.001 per share | DYAI | The NASDAQ Stock Market LLC

Item 8.01 Other Events
On February 21, 2020, Dyadic International, Inc. (the “Company”) announced that data presented at the 15th European Conference on Fungal Genetics (“ECFG15”) demonstrated its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP).
The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd (“VTT”) at the ECFG15 conference in Rome, Italy on Wednesday, February 19. The scientific results are outlined in the presentation entitled, ''Development of filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system.”
A copy of the press release is attached as Exhibit 99.1 and the Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K herein by reference.

Item 9.01 Financial Statements and Exhibits |  |
(d) Exhibits |  |
The following exhibit is being furnished herein: |  |
Exhibit Number |  | Description
99.1 |  | Press Release dated as of February 24, 2020
99.2 |  | VTT presentation entitled "Development of the filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system"

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 24, 2020

Dyadic International, Inc. |
By: | /s/ Mark A. Emalfarb
Name: | Mark A. Emalfarb
Title: | Chief Executive Officer